

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required To Complete This Page**

1. Registrant Name:

NOVO NORDISK PHARMACEUTICALS

2. Address:

500 NEW JERSEY AVENUE, NW, #350, WASHINGTON, DC 20001

3. Principal place of business (if different from line 2):

4. Contact Name: MICHAEL MAWBY

Telephone: 2026264520

E-mail (optional): mmb@novonordisk.com

Senate ID #: 284790-12

House ID #:

7. Client Name: Self

TYPE OF REPORT

8. Year 2007 Midyear (January 1 - June 30): **OR** Year End (July 1 - December 31):

9. Check if this filing amends a previously filed version of this report:

10. Check if this is a Termination Report: => Termination Date: _____ 11. No Lobbying Activity:

INCOME OR EXPENSES

Complete Either Line 12 **OR** Line 13

12. Lobbying Firms

INCOME relating to lobbying activities for this reporting period was:

Less than \$10,000:

\$10,000 or more: => Income (nearest \$20,000): _____

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations

EXPENSES relating to lobbying activities for this reporting period were:

Less than \$10,000:

\$10,000 or more: => Expenses (nearest \$20,000): 300,000.00

14. Reporting Method.

Check box to indicate expense accounting method. See instructions for description of options.

Method A. Reporting amounts using LDA definitions only

Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code

Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

Registrant Name: NOVO NORDISK PHARMACEUTICALS Client Name: Self

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: BUD (one per page)

16. Specific lobbying issues:

Diabetes funding in S. 1710, H.R. 3043, Labor-HHS-Education Appropriations; FDA/Importation provisions in S. 1859, H.R. 3161, Agriculture Appropriations; Importation provision in S. 1644, H.R. 2638, Homeland Security Appropriations;

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES
Health & Human Services, Dept of (HHS)
Nat'l Institutes of Health (NIH)
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: KEENER, PAIGE

Covered Official Position (if applicable): N/A

Name: MAWBY, MICHAEL

Covered Official Position (if applicable): N/A

Name: MCGILL, STEVE

Covered Official Position (if applicable): N/A

Name: MCGOWEN, CHRISTOPHER

Covered Official Position (if applicable): N/A

Name: PORTER, CHRISTOPHER

Covered Official Position (if applicable): N/A

Name: SEMENIUK, LAUREN

Covered Official Position (if applicable): LEGISLATIVE DIRECTOR, REP. CLIFF STEARNS

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: NOVO NORDISK PHARMACEUTICALS Client Name: Self

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: CPT (one per page)

16. Specific lobbying issues:

5. 1145, H.R. 1908, Patent Reform Act; PTO continuation practice reforms

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES
Patent & Trademark Office (PTO)
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: KEENER, PAIGE

Covered Official Position (if applicable): N/A

Name: MAWBY, MICHAEL

Covered Official Position (if applicable): N/A

Name: MCGILL, STEVE

Covered Official Position (if applicable): N/A

Name: MCGOWEN, CHRISTOPHER

Covered Official Position (if applicable): N/A

Name: PORTER, CHRISTOPHER

Covered Official Position (if applicable): N/A

Name: SEMENIUK, LAUREN

Covered Official Position (if applicable): LEGISLATIVE DIRECTOR, REP. CLIFF STEARNS

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: HCR (one per page)

16. Specific lobbying issues:

* S. 755, Diabetes Screening and Medicaid Savings Act H.R. 2762, S. 1494, Reauthorization of Special Diabetes Funding for Type 1 Diabetes and Indians S. 631, Remote Patient Management for Diabetes and Other Chronic Health Care Conditions H.R. 1224, Physical Education Content and Performance Standards in Schools H.R. 2210, Diabetes Prevention Access and Care Act H.R. 2922, Preventing Diabetes in Medicare Act S. 1161, HELP America bill, pre-diabetes medicare provisions H.R. 2241, S. 1391, Diabetes Treatment and Prevention Act S. 242, H.R. 380 Pharmaceutical Market Access and Drug Safety Act of 2007 H.R. 1038, S. 623, Access to Life-Saving Medicine Act, follow-on biologics H.R. 1956, Patient Protection and innovative Biologic Medicines Act of 2007, follow-on biologics S. 1505, Affordable Biologics for Consumers Act of 2007, follow-on biologics S. 1695, Biologics Price Competition and Innovation Act of 2007, follow-on biologics 5 6

17. House(s) of Congress and Federal agencies contacted:

Centers For Disease Control & Prevention (CDC)
HOUSE OF REPRESENTATIVES
Health & Human Services, Dept of (HHS)
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: KEENER, PAIGE

Covered Official Position (if applicable): N/A

Name: MAWBY, MICHAEL

Covered Official Position (if applicable): N/A

Name: MCGILL, STEVE

Covered Official Position (if applicable): N/A

Name: MCGOWEN, CHRISTOPHER

Covered Official Position (if applicable): N/A

Name: PORTER, CHRISTOPHER

Covered Official Position (if applicable): N/A

Name: SEMENIUK, LAUREN

Covered Official Position (if applicable): LEGISLATIVE DIRECTOR, REP. CLIFF STEARNS

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: NOVO NORDISK PHARMACEUTICALS Client Name: Self

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MMM (one per page)

16. Specific lobbying issues:

* H.R. 2058, Helping Fill the Medicare Rx Gap Act of 2007 H.R. 4, S. 3, Medicare Prescription Drug Price Negotiation Act H.R. 3162, Related Senate amendment, CHAMP Act (SCHIP) 7

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: KEENER, PAIGE

Covered Official Position (if applicable): N/A

Name: MAWBY, MICHAEL

Covered Official Position (if applicable): N/A

Name: MCGILL, STEVE

Covered Official Position (if applicable): N/A

Name: MCGOWEN, CHRISTOPHER

Covered Official Position (if applicable): N/A

Name: PORTER, CHRISTOPHER

Covered Official Position (if applicable): N/A

Name: SEMENIUK, LAUREN

Covered Official Position (if applicable): LEGISLATIVE DIRECTOR, REP. CLIFF STEARNS

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: NOVO NORDISK PHARMACEUTICALS Client Name: Self

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: PHA (one per page)

16. Specific lobbying issues:

H.R. 2900, FDA Amendments Act of 2007, PDUFA S. 1082, Prescription Drug User Fee Amendments of 2007, PDUFA H.R. 1561, Enhancing Drug Safety and Innovation Act, PDUFA S. 1156, Best Pharmaceutical for Children Amendments of 2007, pediatric provisions

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: KEENER, PAIGE

Covered Official Position (if applicable): N/A

Name: MAWBY, MICHAEL

Covered Official Position (if applicable): N/A

Name: MCGILL, STEVE

Covered Official Position (if applicable): N/A

Name: MCGOWEN, CHRISTOPHER

Covered Official Position (if applicable): N/A

Name: PORTER, CHRISTOPHER

Covered Official Position (if applicable): N/A

Name: SEMENIUK, LAUREN

Covered Official Position (if applicable): LEGISLATIVE DIRECTOR, REP. CLIFF STEARNS

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Signature: ON FILE Date: Aug 14, 2007

Printed Name and Title: MICHAEL MAWBY, CHIEF GOVERNMENT AFFAIRS OFFICER -

Information Update Page:

Complete ONLY where registration information has changed.

LOBBYIST UPDATE

23. Name of each previously reported individual who is NO LONGER expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issues previously reported that NO LONGER pertain

AFFILIATED ORGANIZATIONS

25. Add the following organization(s)

26. Name of each previously reported organization that is NO LONGER affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities

28. Name of each previously reported foreign entity the NO LONGER owns, OR controls, OR is affiliated with the registrant, client or affiliated organization

Signature: ON FILE Date: Aug 14, 2007

Printed Name and Title: -